`Sent:
`To:
`Cc:
`
`Subject:
`Attachments:
`
`Frank Calvosa
`Monday, June 06, 2016 4:16 PM
`Sarah E. Spires; Sadaf R. Abdullah; Parvathi Kota, Ph.D; 1092CFAD6; 1096CFAD6
`Nick Cerrito; Evangeline Shih; Andrew Chalson; Lyndsey Przybylski;
`'aminsogna@jonesday.com'; 'Patrick Elsevier'; 'gjlarosa@jonesday.com'; Eric Stops
`IPR2015-01092, -1096, -1102, -1103
`Patent Owner Objections IPR2015-01096.pdf; Patent Owner Objections
`IPR2015-01102.pdf; Patent Owner Objections IPR2015-01103.pdf; Patent Owner
`Objections IPR2015-01092.pdf
`
`Counsel,
`
`Attached please find Patent Owner’s Objections to Evidence Submitted with CFAD’s Replies, in the above-referenced
`IPRs.
`
`We note that the date for CFAD to serve supplemental evidence in response to Patent Owner’s objections is June 20,
`which is after the June 16 deadline for motions to exclude. As such, please let us know if CFAD is agreeable to extending
`the deadline for the parties’ motions to exclude from June 16 to June 23.
`
`Further, Celgene has noted that CFAD’s replies exceed the proper scope of a reply under 37 C.F.R. § 42.23(b), as
`described in the attached objections. CFAD’s replies also exceed the word limit set forth in 37 C.F.R. 42.24. Celgene
`intends to request a conference call with the Board to discuss these issues. Please provide CFAD’s availability by no later
`than close of business on June 8.
`
`Thanks,
`
`Frank Calvosa
`
`Associate
`Quinn Emanuel Urquhart & Sullivan, LLP
`
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`212-849-7569 Direct
`212-849-7000 Main Office Number
`212-849-7100 FAX
`frankcalvosa@quinnemanuel.com
`www.quinnemanuel.com
`
`NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named above. This message
`may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader of this message is not the intended
`recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any
`review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately
`by e-mail, and delete the original message.
`
`1
`
`Page 1 of 1
`
`CELGENE EXHIBIT 2069
`Coalition for Affordable Drugs VI LLC (Petitioner) v. Celgene Corporation (Patent Owner)
`Case IPR2015-01102